Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-MDS-1
2023-510361-97-00Phase 3Completed
- Sponsor
- Syros Pharmaceuticals
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Tamibarotene + Azacitidine with Placebo + Azacitidine (2 arms). Primary endpoint: Complete remission/complete response rate. Started Jun 2024; status: completed.
02
Drugs
tamibarotene
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2023-510361-97-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510361-97-00.